INDEMNITY AGREEMENTIndemnity Agreement • May 19th, 2021 • Janux Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of ___________ _____, 20__, is made by and between JANUX THERAPEUTICS, INC., a Delaware corporation (the “Company”), and _________________ (“Indemnitee”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • May 19th, 2021 • Janux Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of April 15, 2021, by and among Janux Therapeutics, Inc., a Delaware corporation (the “Company”), and the investors set forth on the Schedule of Investors attached hereto as Schedule A (each, an “Investor” and collectively, the “Investors”). This Agreement amends and restates and supersedes in its entirety that certain Amended and Restated Investors’ Rights Agreement executed by the Company and certain of the Investors on March 1, 2021 (the “Prior Agreement”).
CELL LINE LICENSE AGREEMENTLine License Agreement • May 19th, 2021 • Janux Therapeutics, Inc. • Pharmaceutical preparations
This Cell Line License Agreement (“Agreement”), effective as of April 19, 2021 (“EFFECTIVE DATE”), is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”) and Janux Therapeutics, Inc., having its principal place of business at 11099 N. Torrey Pines Road, La Jolla, California 92037, USA. WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties”.
RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT by and between JANUX THERAPEUTICS, INC. and MERCK SHARP & DOHME CORP.Research Collaboration and Exclusive License Agreement • May 19th, 2021 • Janux Therapeutics, Inc. • Pharmaceutical preparations • New York
This Research Collaboration and Exclusive License Agreement (this “Agreement”) is effective as of December 15, 2020, (the “Effective Date”) and is entered into by and between Janux Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, having an address at 11099 Torrey Pines Park Road, Suite 290, San Diego, CA 92037 (“Company”) and Merck Sharp & Dohme Corp., a corporation organized and existing under the laws of New Jersey with its principal business office located at One Merck Drive, Whitehouse Station, NJ 08889 (“Merck”).
SUPPORT SERVICES AGREEMENTSupport Services Agreement • May 19th, 2021 • Janux Therapeutics, Inc. • Pharmaceutical preparations • California
THIS SUPPORT SERVICES AGREEMENT (this “Agreement”) is made and entered into as of January 1, 2021 (the “Effective Date”), by and between JANUX THERAPEUTICS, INC., a Delaware Corporation (the “Company”), and COI PHARMACEUTICALS, INC., a Delaware Corporation (the “Service Provider”).
January 1, 2021 David CampbellJanux Therapeutics, Inc. • May 19th, 2021 • Pharmaceutical preparations
Janux Therapeutics, Inc. (the “Company”) is pleased to offer you at-will employment in the position of President and Chief Executive Officer on the terms and conditions set forth in this letter agreement (the “Agreement”).
CONSULTING AGREEMENTConsulting Agreement • May 19th, 2021 • Janux Therapeutics, Inc. • Pharmaceutical preparations • California
THIS CONSULTING AGREEMENT (this “Agreement”) is made as of March 10, 2021 (the “Effective Date”) by and between JANUX THERAPEUTICS, INC., a Delaware corporation (“Janux” or the “Company”), and SHEILA GUJRATHI, M.D. (“Consultant”).
